158 related articles for article (PubMed ID: 20961861)
1. Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo.
Maasch C; Vater A; Buchner K; Purschke WG; Eulberg D; Vonhoff S; Klussmann S
J Biol Chem; 2010 Dec; 285(51):40012-8. PubMed ID: 20961861
[TBL] [Abstract][Full Text] [Related]
2. HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.
Watanabe M; Sheriff S; Lewis KB; Tinch SL; Cho J; Balasubramaniam A; Kennedy MA
Cancer Lett; 2012 Feb; 315(1):18-27. PubMed ID: 22036895
[TBL] [Abstract][Full Text] [Related]
3. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.
Liau SS; Rocha F; Matros E; Redston M; Whang E
Cancer; 2008 Jul; 113(2):302-14. PubMed ID: 18473350
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells.
Liau SS; Jazag A; Ito K; Whang EE
Br J Cancer; 2007 Mar; 96(6):993-1000. PubMed ID: 17342093
[TBL] [Abstract][Full Text] [Related]
5. HMGA and Cancer: A Review on Patent Literatures.
De Martino M; Fusco A; Esposito F
Recent Pat Anticancer Drug Discov; 2019; 14(3):258-267. PubMed ID: 31538905
[TBL] [Abstract][Full Text] [Related]
6. Molecular aspects on adriamycin interaction with hmga1 regulatory region and its inhibitory effect on HMGA1 expression in human cervical cancer.
Akhter MZ; Luthra K; Rajeswari MR
J Biomol Struct Dyn; 2016; 34(4):877-91. PubMed ID: 26084422
[TBL] [Abstract][Full Text] [Related]
7. Netropsin improves survival from endotoxaemia by disrupting HMGA1 binding to the NOS2 promoter.
Grant MA; Baron RM; Macias AA; Layne MD; Perrella MA; Rigby AC
Biochem J; 2009 Feb; 418(1):103-12. PubMed ID: 18937643
[TBL] [Abstract][Full Text] [Related]
8. Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer.
Méndez O; Peg V; Salvans C; Pujals M; Fernández Y; Abasolo I; Pérez J; Matres A; Valeri M; Gregori J; Villarreal L; Schwartz S; Ramon Y Cajal S; Tabernero J; Cortés J; Arribas J; Villanueva J
Clin Cancer Res; 2018 Dec; 24(24):6367-6382. PubMed ID: 30135148
[TBL] [Abstract][Full Text] [Related]
9. A mouse model study of toxicity and biodistribution of a replication defective adenovirus serotype 5 virus with its genome engineered to contain a decoy hyper binding site to sequester and suppress oncogenic HMGA1 as a new cancer treatment therapy.
Hassan F; Lossie SL; Kasik EP; Channon AM; Ni S; Kennedy MA
PLoS One; 2018; 13(2):e0192882. PubMed ID: 29462157
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications.
Maasch C; Buchner K; Eulberg D; Vonhoff S; Klussmann S
Nucleic Acids Symp Ser (Oxf); 2008; (52):61-2. PubMed ID: 18776253
[TBL] [Abstract][Full Text] [Related]
11. [Effects of small interfering RNA specific to stably transfected HMGA1 gene on biological characters of ovarian carcinoma cells].
Liu YL; Zheng JH
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):51-5. PubMed ID: 20367927
[TBL] [Abstract][Full Text] [Related]
12. High-mobility-group A1 (HMGA1) proteins down-regulate the expression of the recombination activating gene 2 (RAG2).
Battista S; Fedele M; Martinez Hoyos J; Pentimalli F; Pierantoni GM; Visone R; De Martino I; Croce CM; Fusco A
Biochem J; 2005 Jul; 389(Pt 1):91-7. PubMed ID: 15713121
[TBL] [Abstract][Full Text] [Related]
13. A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation.
Hoehlig K; Johnson KW; Pryazhnikov E; Maasch C; Clemens-Smith A; Purschke WG; Vauléon S; Buchner K; Jarosch F; Khiroug L; Vater A; Klussmann S
Br J Pharmacol; 2015 Jun; 172(12):3086-98. PubMed ID: 25659966
[TBL] [Abstract][Full Text] [Related]
14. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer(®) therapeutics.
Vater A; Klussmann S
Drug Discov Today; 2015 Jan; 20(1):147-55. PubMed ID: 25236655
[TBL] [Abstract][Full Text] [Related]
15. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.
Baldassarre G; Belletti B; Battista S; Nicoloso MS; Pentimalli F; Fedele M; Croce CM; Fusco A
Oncogene; 2005 Oct; 24(45):6809-19. PubMed ID: 16007157
[TBL] [Abstract][Full Text] [Related]
16. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
17. The High Mobility Group A1 (HMGA1) Chromatin Architectural Factor Modulates Nuclear Stiffness in Breast Cancer Cells.
Senigagliesi B; Penzo C; Severino LU; Maraspini R; Petrosino S; Morales-Navarrete H; Pobega E; Ambrosetti E; Parisse P; Pegoraro S; Manfioletti G; Casalis L; Sgarra R
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31167352
[TBL] [Abstract][Full Text] [Related]
18. High mobility group A1 is a molecular target for MYCN in human neuroblastoma.
Giannini G; Cerignoli F; Mellone M; Massimi I; Ambrosi C; Rinaldi C; Dominici C; Frati L; Screpanti I; Gulino A
Cancer Res; 2005 Sep; 65(18):8308-16. PubMed ID: 16166307
[TBL] [Abstract][Full Text] [Related]
19. An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells.
Kim YH; Sung HJ; Kim S; Kim EO; Lee JW; Moon JY; Choi K; Jung JE; Lee Y; Koh SS; Rhee SG; Heo K; Kim IH
Cancer Lett; 2011 Dec; 313(1):76-83. PubMed ID: 21963224
[TBL] [Abstract][Full Text] [Related]
20. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs.
D'Angelo D; Mussnich P; Rosa R; Bianco R; Tortora G; Fusco A
BMC Cancer; 2014 Nov; 14():851. PubMed ID: 25409711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
